(688293)"SHANGHAI OPM BIOSCIENCES CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688293 · · 21 pages · Chinese
Summary by 6ix AI
The report highlights a notable increase in revenue compared to the previous year, alongside a decrease in net profit attributable to shareholders due to acquisition-related accounting impacts. It also discusses the integration of a newly acquired subsidiary and its effects on the company's financial performance and operational capabilities. The filing includes a comprehensive overview of shareholder information and risk factors associated with goodwill impairment and financial liabilities.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai OPM Biosciences Co., Ltd. on 6ix
Earlier from Shanghai OPM Biosciences
- (688293)"SHANGHAI OPM BIOSCIENCES CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
- (688293)"SHANGHAI OPM BIOSCIENCES CO., LTD."Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026
- (688293)"SHANGHAI OPM BIOSCIENCES CO., LTD."Announcement on Resolutions of the 1st Meeting of the 3rd Board of Directors
- (688293)"SHANGHAI OPM BIOSCIENCES CO., LTD."Announcement on Election of Employee Representative Director for the Board of Directors
- (688293)"SHANGHAI OPM BIOSCIENCES CO., LTD."Announcement on Completion of Election of New Board of Directors and Appointment of Senior Executives and Securities Affairs Representative
Later from Shanghai OPM Biosciences
All Shanghai OPM Biosciences news releasesFollow Shanghai OPM Biosciences into a list and get an email when it puts out news.
Follow Shanghai OPM Biosciences